Brief: Sellas Life Sciences Independent Data Monitoring Committee Recommends Galinpepimut-S Regal Trial To Continue As Planned

Sellas Life Sciences

18/04/2023 13:33

April 18 (Reuters) - Sellas Life Sciences Group Inc
 SLS.O :
    * SELLAS LIFE SCIENCES INDEPENDENT DATA MONITORING COMMITTEE
RECOMMENDS GALINPEPIMUT-S REGAL TRIAL TO CONTINUE AS PLANNED
    * SELLAS LIFE SCIENCES GROUP INC - REGAL ON TRACK FOR
INTERIM
ANALYSIS BY LATE 2023/EARLY 2024
    * SELLAS LIFE SCIENCES GROUP INC - A POSITIVE REVIEW OF
ONGOING
PHASE 3 REGAL CLINICAL TRIAL OF GALINPEPIMUT-S (GPS) IN ACUTE
MYELOID LEUKEMIA
    * SELLAS LIFE SCIENCES GROUP- INDEPENDENT DATA MONITORING
COMMITTEE PERFORMED ROUTINE, PRESPECIFIED RISK-BENEFIT
ASSESSMENT OF UNBLINDED DATA FROM STUDY
    * SELLAS LIFE SCIENCES GROUP INC - INDEPENDENT DATA
MONITORING
COMMITTEE (IDMC) HAS RECOMMENDED THAT TRIAL CONTINUE WITHOUT
MODIFICATIONS

Source text for Eikon:  ID:nGNX3hHp5K 
Further company coverage:  SLS.O